Thomas Patrick Kelly, Chief Financial Officer at Xenon Pharmaceuticals Inc. (XENE), bought 15,000 shares at $37.32 ($560K) on 2026-09-30, disclosed to the SEC on 2026-10-01.
Xenon Pharmaceuticals CFO Thomas Patrick Kelly purchased $559,740 worth of shares at $37.32, marking the largest insider purchase in the company's history. This significant buyback by C-suite leadership comes as the stock has crashed nearly 40% over the last 90 days.
XENE is trading at $37.17, a 39.03% decline over the last 90 days and 48.73% below its 52-week high of $72.50, putting it just 3.02% above the 52-week low of $36.08.
1) FDA decision on the azetukalner NDA for focal-onset seizures expected by September 27, 2026. 2) The company is pausing enrollment in Phase 3 psychiatry studies for major depressive disorder and bipolar disorder to review tolerability, a key development announced on September 17, 2026. 3) The trade itself is a catalyst, as it represents the largest insider purchase ever recorded for the company.
The stock faces significant risk due to the voluntary pause in enrollment for its Phase 3 psychiatry studies for major depressive disorder and bipolar disorder following adverse events, which has caused the stock to lose over 30% in recent days.
Something here stands out, but not much.